Provided by Tiger Trade Technology Pte. Ltd.

Altimmune, Inc.

5.41
+0.14312.72%
Volume:1.90M
Turnover:10.12M
Market Cap:564.82M
PE:-5.13
High:5.50
Open:5.29
Low:5.17
Close:5.27
52wk High:9.59
52wk Low:2.90
Shares:104.34M
Float Shares:104.00M
Volume Ratio:0.66
T/O Rate:1.83%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0561
EPS(LYR):-1.3388
ROE:-52.61%
ROA:-30.87%
PB:3.04
PE(LYR):-4.04

Loading ...

Immunocore presents Phase 1 data for hepatitis B candidate at AASLD’s The Liver Meeting

GlobeNewswire
·
Nov 07

BRIEF-Altimmune Files For Offering Of Common Stock Of Up To $200 Million - Filing

Reuters
·
Nov 07

Altimmune Inc Files for Mixed Shelf of up to $400 Mln - SEC Filing

THOMSON REUTERS
·
Nov 07

Altimmune: Files for Offering of Common Stock of up to $200 Mln - Filing

THOMSON REUTERS
·
Nov 07

BRIEF-Altimmune Amends Loan And Security Agreement With Hercules Capital - SEC Filing

Reuters
·
Nov 06

Altimmune Inc - Amends Loan and Security Agreement With Hercules Capital - SEC Filing

THOMSON REUTERS
·
Nov 06

Altimmune Inc - Term Loan Increased From $100 Mln to $125 Mln - SEC Filing

THOMSON REUTERS
·
Nov 06

Altimmune Q3 revenue beats expectations

Reuters
·
Nov 06

Altimmune Q3 Basic EPS USD -0.21

THOMSON REUTERS
·
Nov 06

Altimmune Announces Third Quarter 2025 Financial Results and Business Updates

THOMSON REUTERS
·
Nov 06

Immunocore reports third quarter financial results and provides a business update

GlobeNewswire
·
Nov 06

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Nov 06

Altimmune Inc expected to post a loss of 28 cents a share - Earnings Preview

Reuters
·
Nov 04

Syndax Announces Compelling Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Data Accepted for Presentation at ASH 2025

GlobeNewswire
·
Nov 03

Altimmune Announces Early Completion of Enrollment in Reclaim Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder

THOMSON REUTERS
·
Nov 03

Metsera the US obesity biotech at centre of Novo, Pfizer bidding war

Reuters
·
Oct 31

H.C. Wainwright Sticks to Their Buy Rating for Altimmune (ALT)

TIPRANKS
·
Oct 29

PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

GlobeNewswire
·
Oct 24

Altimmune Price Target Maintained With a $12.00/Share by HC Wainwright & Co.

Dow Jones
·
Oct 20

BUZZ-U.S. STOCKS ON THE MOVE- SLB NV, Bank OZK, Gilead Sciences

Reuters
·
Oct 18